iShares Trust - iShares Biotechnology ETF

NasdaqGM:IBB Stock Report

Market Cap: US$6.6b

iShares Trust - iShares Biotechnology ETF Balance Sheet Health

Financial Health criteria checks 4/6

iShares Trust - iShares Biotechnology ETF has a total shareholder equity of $7.0B and total debt of $754.2M, which brings its debt-to-equity ratio to 10.8%. Its total assets and total liabilities are $7.8B and $804.1M respectively.

Key information

10.8%

Debt to equity ratio

US$754.22m

Debt

Interest coverage ration/a
CashUS$808.41m
EquityUS$6.96b
Total liabilitiesUS$804.09m
Total assetsUS$7.76b

Recent financial health updates

No updates

Recent updates

iShares Biotechnology ETF: Playing Defense

Dec 10

IBB: A Near-20x P/E Is Historically Pricey, Technical Trends Neutral

Oct 14

iShares Biotechnology ETF: Significant Upside Potential As Sector Gains Momentum

Jul 28

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs

Jul 09

IBB: Let It Rest

Mar 26

IBB ETF: On Sale And Rich Option Premium To Boot

Sep 20

IBB: Biotechnology Offers A Compelling Opportunity As It Builds Up Momentum

Jul 19

IBB: M&As Are Back

Jun 21

XBI Or IBB: How To Play The Oversold Biotech Most Efficiently

Jun 09

IBB: Lows After Highs Highlight Failing Growth Narratives And Overvaluation In Biotech Sector

May 09

IBB: Healthcare Dashboard For April

Apr 18

XBI And IBB: You May Keep Laughing While We Keep Buying This March 2020-Like Opportunity

Jan 28

Biotech Investing: Large Trading Volumes Suggest Better Days Are Ahead

Jan 17

IBB And XBI: 4 Reasons To Buy Biotech Stocks Ahead Of 2022

Dec 06

IBB: Healthcare Dashboard For October

Oct 15

IBB: Risks And Hedging

Sep 21

IBB: Growth And Innovation

Jun 28

AbbVie rated buy at Mizuho despite patent cliff for Humira

Jan 11

NASDAQ Biotech Index cross 5,000-mark as vaccine makers and gene-editors surge

Jan 08

iShares Nasdaq Biotechnology ETF: Continuous Innovation For Mankind

Jan 06

Citing uncertainty, Baird stays neutral on Biotech for 2021

Jan 04

COVID-19 vaccine makers: Looking back on 2020 seeking insights for 2021

Dec 31

Financial Position Analysis

Short Term Liabilities: IBB's short term assets ($809.8M) exceed its short term liabilities ($803.6M).

Long Term Liabilities: IBB's short term assets ($809.8M) exceed its long term liabilities ($451.8K).

Debt to Equity History and Analysis

Debt Level: IBB has more cash than its total debt.

Reducing Debt: IBB's debt to equity ratio has reduced from 11.4% to 10.8% over the past 5 years.

Debt Coverage: Insufficient data to determine if IBB's debt is well covered by operating cash flow.

Interest Coverage: Insufficient data to determine if IBB's interest payments on its debt are well covered by EBIT.

Balance Sheet

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 02:45
End of Day Share Price 2025/01/31 00:00
Earnings2023/09/30
Annual Earnings2023/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

iShares Trust - iShares Biotechnology ETF is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution